FRANKLIN TEMPLETON | ClearBridge

ClearBridge Large Cap Value Portfolios

Commentary | as of September 30, 2026

Key Takeaways

- **Markets:** US stocks continued to rise in the third quarter, with returns shaped by two major macro forces: the oil supply shock stemming from tensions in the Middle East driving oil prices higher and, partly a result of this, higher inflation expectations and bond yields. The benchmark Russell 1000 Value Index returned 2.6%. The Fed raised interest rates for the first time since 2023 in September and grew more hawkish in its forecasts, implying another hike in 2026; the 10-year Treasury yield finished the quarter up roughly 70 basis points at 5.3%. Sector performance in the index was mixed, with energy leading on higher oil prices, information technology (IT) and communication services lifted by hyperscaler strength, health care continuing its rebound and consumer and rate-sensitive sectors flat to down as a result of inflation and rate pressure.
- **Contributors:** On an individual stock basis, the largest contributors to relative returns were Thermo Fisher Scientific, ConocoPhillips, Waters, McKesson and not owning IBM. On a relative basis, stock selection in financials and industrials contributed to performance. A lack of exposure to real estate, an overweight to health care and an underweight to consumer staples also contributed to performance.
- **Detractors:** The largest detractors were CVS Health, XPO, WEC Energy Group, Microchip Technology and an underweight to Microsoft. Stock selection in IT, health care, materials and energy detracted from performance.
- **Outlook:** We continue to favor quality businesses with durable franchises, strong balance sheets and proven management teams, purchased with valuation discipline and assembled through risk-aware portfolio construction. Whether the economy accelerates or weakens, we believe these companies can compound earnings or provide downside mitigation. As narrow leadership and speculative, lower-quality performance recede, we expect the portfolio's diversified quality orientation to become increasingly valuable and apparent.

Top Equity Issuers (% of Total)

Holding	Portfolio
Apple Inc	6.09
Amazon.com Inc	5.19
JPMorgan Chase & Co	4.34
Microsoft Corp	3.83
Johnson & Johnson	3.78
Intel Corp	2.74
Thermo Fisher Scientific Inc	2.74
Parker-Hannifin Corp	2.19
ExxonMobil Holdings Corp	2.18
CVS Health Corp	2.18

Performance Review

- Weaker stock selection in information technology, health care, materials and energy more than offset favorable sector allocation and strong stock selection in industrials and financials. The market's narrow, higher-beta leadership also challenged our quality-oriented approach.
- An underweight to Microsoft was a leading relative detractor, as strong Azure growth and increasing Copilot adoption reinforced confidence in the company's ability to monetize AI investment. CVS Health also detracted as investors focused on pressure in its 340B business, expected Caremark membership declines and related litigation. We maintained our overweight because we see a path to margin expansion as CVS recovers profits in Medicare Advantage.
- Thermo Fisher Scientific was a leading relative contributor, supported by stronger-than-expected results, improving customer activity and increased full-year guidance. Waters and McKesson also contributed. Waters is generating encouraging early synergies from its acquisition of Becton Dickinson's biosciences and diagnostic solutions businesses, while McKesson benefited from strong results, higher prescription volumes and a raised outlook.
- We maintained our quality and valuation discipline as the Russell 1000 Value rebalancing and speculative AI leadership created relative-performance challenges. We continued to favor durable franchises with strong competitive positions, balance sheets and cash-flow generation.
- During the quarter, we initiated positions in Nvidia and Coca-Cola and exited Chevron, PepsiCo and Roche. We view Nvidia as a high-quality, cash-flow-generative franchise with strong competitive positioning and an increasingly attractive valuation. Coca-Cola offers strong brands, a global footprint and robust pricing power. The PepsiCo and Roche exits reflected challenges to our investment theses, while the Chevron sale funded higher-conviction exposure to ExxonMobil.

Outlook

- We continue to adhere to our philosophy of seeking quality businesses with durable franchises, strong balance sheets and proven management teams, purchased with valuation discipline and assembled through risk-aware portfolio construction. We believe this discipline is particularly important given elevated valuations and the market's increasingly narrowing focus on lower-quality AI players, which up until the June Russell rebalancing represented a meaningful and growing part of the benchmark. Over the past year, the outperformance of high-beta, lower-quality, more commoditized stocks over lower-beta, higher-quality stocks has produced what we view as a historic low-quality, or "junk," rally.
- While that environment has obscured the portfolio's defensive characteristics, we like the setup going forward. If the economy accelerates, the quality franchises we favor should be positioned to compound earnings, while improved investor confidence could help close their valuation discounts. If the economy weakens, their durable business models, balance-sheet strength and earnings resilience should provide downside mitigation after a period in which those characteristics have received little recognition from the market.
- We do not have a strong conviction that either economic scenario must prevail; our positioning reflects our view, rather, that the current combination of narrow market leadership, unusually strong performance of speculative stocks and rapidly expanding valuations among cyclical AI beneficiaries will not persist indefinitely. In a market with broader leadership and greater emphasis on earnings durability, cash generation and balance-sheet strength, we believe the portfolio's diversified quality orientation should become increasingly valuable and apparent.

Not FDIC Insured | No Bank Guarantee | May Lose Value

Average annual total returns (%) - as of September 30, 2026-PRELIMINARY

Composite	3-Mo*	6-Mo*	YTD*	1-Yr	3-Yr	5-Yr	10-Yr	15-Yr	20-Yr	25-Yr	Inception	Inception Date
Net of Fees	-0.30	8.80	10.75	12.31	13.00	7.74	9.09	10.41	6.76	–	6.91	6/30/2002
Pure Gross of Fees	0.20	9.88	12.40	14.56	15.26	9.90	11.28	12.62	8.91	–	9.07	6/30/2002
Benchmark	2.61	16.81	19.27	23.81	20.07	11.92	11.43	12.98	8.60	–	9.22	–

*Cumulative total returns

Benchmark(s)

Benchmark =Russell 1000 Value Index

The strategy returns shown are preliminary composite returns, subject to future revision (downward or upward).

ClearBridge Investments, LLC claims compliance with the Global Investment Performance Standards (GIPS®). GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.
To obtain specific information on available products and services or a GIPS Report, contact your Franklin Templeton separately managed account sales team at (800) DIAL BEN/342-5236.
Past performance is not a guarantee of future results. An investment in this strategy can lose value. Please visit www.franklintempleton.com for the latest performance figures. Investors cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expenses or sales charges.

Fees: Returns for periods less than one year are not annualized. Pure gross of fee returns do not reflect the deduction of any expenses, including transaction costs. Net Composite Returns referenced above represent Pure Gross Composite performance of the portfolio reduced by an annual fee of 2.02%, the maximum fee charged by Primerica Advisors to clients invested in the strategy through the Primerica Advisors Lifetime Investment Program wrap fee program. The Net of fee composite returns presented in the attached strategy GIPS Report are calculated by reducing each monthly composite pure gross rate of return by the highest "bundled" fee charged (3.00%) annually, prorated to a monthly ratio. Returns reflect the reinvestment of dividends and other earnings. All performance is reported in US dollars. Management and performance of individual accounts may vary for reasons that include the existence of different implementation practices and model requirements in different investment programs.
The composite is comprised of accounts that are separately managed accounts (SMAs) managed in accordance with the strategy.
For investors that access strategies through the Primerica Advisors Lifetime Investment Program, Primerica Advisors or its service providers, not Franklin Templeton Private Portfolio Group, LLC (FTPPG), is responsible for implementing the strategy in your account. Gross performance of the strategy, as implemented by Primerica Advisors, will vary from FTPPG's composite performance. Net performance for individual investors will vary based on the fees charged by Primerica Advisors, as well as Primerica Advisors' management of its program and each client's account.

What are the Risks?

All investments involve risks, including possible loss of principal. Small- and mid-cap stocks involve greater risks and volatility than large-cap stocks. **International investments** are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in **emerging markets**.

Glossary

A **basis point (bp, or bps)** is one one-hundredth of one percent (1/100% or 0.01%).

Earnings per share (EPS) is defined as a company's net income divided by the number of outstanding shares of its common stock.

Important Information

The information provided is not a complete analysis of every material fact regarding any country, market, industry, security or portfolio. Because market and economic conditions are subject to change, comments, opinions and analyses are rendered as of the date of this material and may change without notice. A portfolio manager's assessment of a particular security, investment or strategy is not intended as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy; it is intended only to provide insight into the portfolio's selection process. Holdings are subject to change.

These materials are being provided for illustrative and informational purposes only. The information contained herein is obtained from multiple sources that are believed to be reliable. However, such information has not been verified, and may be different from the information included in documents and materials created by the sponsor firm in whose investment program a client participates. Some sponsor firms may require that these materials be preceded or accompanied by investment profiles or other documents or materials prepared by such sponsor firms, which will be provided upon a client's request. For additional information, documents and/or materials, please speak to your Financial Professional or contact your sponsor firm.

Franklin Templeton (FT) is not undertaking to provide impartial advice. Nothing herein is intended to provide fiduciary advice. FT has a financial interest.

The **Russell 1000 Value Index** measures the performance of the large-cap value segment of the U.S. equity universe.

Source: FTSE.

Important data provider notices and terms available at www.franklintempletondatasources.com. All data is subject to change.

Holdings are provided for informational purposes only and should not be construed as a recommendation to purchase or sell any security.

Separately Managed Accounts (SMAs) are investment services provided by Franklin Templeton Private Portfolio Group, LLC (FTPPG), a federally registered investment advisor. Client portfolios are managed based on investment instructions or advice provided by one or more of the following Franklin Templeton affiliated sub-advisors: ClearBridge Investments, LLC. Management is implemented by FTPPG, the designated sub-advisor or, in the case of certain programs, the program sponsor or its designee.

ClearBridge Investments, LLC is a Franklin Templeton affiliated company.

© Franklin Templeton. All rights reserved.

This material is intended for informational purposes only, and it is not intended to be relied on to make any investment decision. Franklin Templeton, LLC, is not affiliated with Primerica or PFS Investments, Inc.

FRANKLIN TEMPLETON